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ABSTRACT 
Objective: To evaluate the survival of the patients with heart failure in the Cardiology Center in Tirana, to evaluate the cost effectiveness of 
carvedilol versus metoprolol. 
Methods: 
Results: There were included 239 patients of mild, moderate and severe heart failure, NYHA II-IV, with the fraction of ejection<50 hospitalized 
in the University clinic of cardiology of Tirana, followed for a two-year period; 83 patients (34.7%) were treated with Carvedilol; 70 patients 
(29.2%) were treated with metoprolol, 21 patients were treated with nebivolol (8.7%), and 65 patients (27.1%) were treated only with the 
traditional therapy (TTh). 
239 patients (pts) suffering chronic heart failure of different aetiologies, on traditional treatment for heart failure (angiotensin-
converting enzyme inhibitors, diuretics, digoxin), with ejection fraction<50%, in NYHA class II-IV, were randomised to carvedilol 6.25-25 mg/day, 
or metoprolol 50-100 mg/day, or nebivolol 5 mg/day or treated only with the traditional treatment for they have contraindications regarding the 
use of β–blockers, followed for a two-year period.  
Conclusion: The use of carvedilol along with the traditional therapy of heart failure assures a higher survival rate and a lower hospitalization rate 
but an increase of cost of treatment of 216 €a year compared to metoprolol in addition with traditional therapy. 
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INTRODUCTION 
The use of beta-blockers has been shown to improve survival in 
patients with chronic heart failure (CHF) and the benefit of the three 
agents, carvedilol [1, 2] metoprolol [1, 3] and bisoprolol, [4, 5] was 
demonstrated. The COMET study showed that carvedilol reduced 
mortality compared to metoprolol tartrate in patients with mild-
moderate heart failure and left ventricular systolic dysfunction [4]. 
These drugs block beta1-adrenergic receptors, but only carvedilol 
blocks beta2-and alpha1
The comprehensive adrenergic blockade of carvedilol leads to a greater 
sympatho-inhibitory effect than metoprolol [8-10]. At the same time 
carvedilol, but not metoprolol leads to persistent beta-blockade beyond 
its plasma elimination, due to binding to an allosteric site of human β-
adrenoceptors with slower kinetics [11]. Carvedilol significantly 
decreases systemic blood pressure, pulmonary artery pressure, and 
pulmonary capillary wedge pressure because of the vasodilatation that 
occurs with blocking of β -receptors. Blocking of ß-receptors reduces the 
heart rate and increases diastolic filling time [12]. 
-adrenergic receptors and have at the same 
time antiproliferative, antioxidant, and anti-endothelin actions [6, 7].  
Our aim was to estimate the effects in survival of two treatments of 
heart failure; carvedilol β1, β2 β-blocker and metoprolol selective 
β1
MATERIALS AND METHODS 
–blocker. The average daily costs of hospitalization and the costs 
of the treatment were calculated. It was the first time that a cost-
effectiveness study between β-blockers was performed in the 
national clinic of cardiology in Tirana, Albania (QSUT).  
In the double blind prospective study were included 239 
patients of mild, moderate and severe heart failure, NYHA II-IV, 
with the fraction of ejection less than 50%, hospitalized in the 
University Clinic of Cardiology of Tirana, followed for a two-year 
period. According to the type of their medication, the patients 
were divided in four groups.  
First group: traditional therapy+carvedilol (6.25-25 mg/d);  
Second group: traditional therapy+metoprolol(50-100 mg/d); 
Third group: traditional therapy+nebivolol, (5 mg/d); 
Fourth group and at the same time control group: only traditional 
therapy, TTh (Diuretics, ACEI/ARB, Digoxin) 
Written informed consent was obtained from all patients. In a three 
months time period an echocardiography examination over the 
patients under study was performed.  
To have a larger view of the necessary economic values for the 
treatment of CHF, the annual costs of treatment must be calculated. 
It was calculated the daily cost of drugs for every patient, daily cost 
of medical analysis and tests for every patient, days of standing in 
the hospital and the value of hospital secondary expenses. 
The hospital cost for every patient was calculated; at the same time using 
the daily cost of drugs for every patient, we are able to find the cost of the 
treatment for the period out of the hospital for every patient. 
The total of the hospital costs for every patient with respective out 
of hospital costs per patient, gives us the annual cost of every 
patient. To all cost values found we have given the averages. 
We have studied the average annual cost for the two types of treatment 
schemes (Traditional treatment+Carvedilol; Traditional treatment+ 
Metoprolol) and we have to find the difference between them.  
Statistical methods like ANOVA, Kaplan-Meir Curves, Cox Regression 
were applied. [13-19] 
Exclusion criteria 
Patients diagnosed with acute myocardial infarction or unstable 
angina in two previous months, with valvular disease, with 
untreated arrhythmia, or patents who had undergone a major 
surgical procedure within three months, patients with systolic blood 
pressure of more than 160 or less than 85 mm Hg or diastolic blood 
pressure of more than 100 mm Hg; patients with a heart rate of less 
than 68 beats per minute, or patients with clinically important 
hepatic or renal disease, were excluded from our study. 
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RESULTS 
There were included 239 patients of mild, moderate and severe 
heart failure, NYHA II-IV, with the fraction of ejection<50 
hospitalized in the University clinic of cardiology of Tirana, followed 
for a two-year period; 83 patients (34.7%) were treated with 
Carvedilol; 70 patients (29.2%) were treated with metoprolol, 21 
patients were treated with nebivolol (8.7%), and 65 patients 
(27.1%) were treated only with the traditional therapy (TTh).  
 
Fig. 1: The patient`s percentage treated in each group 
 
 
Fig. 2: The Kaplan–Meier model for all patients 
 
Fig. 3: The Survival Function (Kaplan–Meier model) according 
to the gender 
 
Survival Function (Kaplan–Meier model) according the gender has 




Fig. 4: The survival function (kaplan–meier model) according to 
the type of medication
Table 1: Medications used for each group 









Diuretics 50 (60.2) 42 (51.2) 18 (85.7) 46 (70.1) 0.007 
Aldosteron Antagonists 9 (10.8) 21(30.2) 3 (14.2) 52 (80.0) 0.027 
ACE-inh 63 (75.9) 62 (88.4) 16 (76.9) 48 (73.8) 0.013 
ARBs 15 (18.0) 5 (6.9) 5 (23.8) 10 (15.4) 0.041 
Digitalis 23 (27.7) 16 (23.3) 3 (14.2) 32 (49.2) 0.037 
Antiarrhythmics 0 (0.0) 0 (0.0) 0 (0.0) 17 (26.2) 0.001 
Nitrites 7 (8.4) 18 (25.6) 3 (14.2) 21 (25.3) 0.005 
B-Blockers 83 (100.0) 70 (100.0) 21 (100.0) 0 (0.0) <0.001 
Anticoagulants 23 (27.7) 11 (16.9) 1(4.7) 21 (32.3) 0.001 
Aspirin 37 (44.6) 47 (67.4) 4 (19.0) 37 (56.9) 0.001 
Mean age of First group: traditional therapy (TTh)+carvedilol, was 59.6 years±9.86; Mean age of Second group: TTh+metoprolol, 58.5 years±10.3, 
Mean age of Third group: traditional therapy+Nebivolol, mean age 62 years±9.36Mean age of Fourth group: only TTh(Diuretics, ACEI/ARB, Digoxin) 
was 63.9±10.3, without any statistical difference between them (p=0.071). 
 
Table 2: The NYHA and the number of deaths in each group 
Characteristics Type of therapy n (%) p-
value Carvedilol n=83(34.7%) Metoprololn=70(29.2%) Nebovolol n=21(8.7%) Control group n=65(27.1%) 
NYHA II 34 (41.0) 33 (47.1) 11 (52.4) 22 (33.7) 0.116 
NYHA III 29 (35.0) 29 (41.9) 9 (42.9) 28 (42.5) 0.089 
NYHA IV 20 (24.0) 8 (11.4) 1 (4.8) 15 (23.8) 0.001 
EF (mean±SD) 0.42±0.09 0.47±0.10 0.44±0.11 0.42±0.83 0.234 
Nr of deaths 5 (6.0) 8 (11.4) 0 (0.0) 10 (15.4) 0.001 
The number of deaths was higher in the control group, 10 (15.4%), in Metoprolol group was 8 (11.4%), and in Carvedilol group was 5(6%); 
p=0.001. There were not deaths in Nebivolol group. The number of patients in this group is smaller than the other groups. (21 patients only). The 
function of survival was performed with KAPLAN-Meier method for the entire sample as well as for special subgroups to compare them.  
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Based to this results, we conclude that patients who have use 
Carvedilol in addition with traditional therapy have a higher 
probability to survive. They are followed from the patients who had 
used Metoprolol in addition with traditional therapy. The lower 
probability to survive was for the fourth group (they do not use β-
blocker),The Cox model of the Hazard Function was built taking into 
consideration the factors which influence the risk of death such as 
age, gender, etiology of dilatation, type of treatment. 
 
Table 3: The Cox’s model results of the Hazard Function controlled for gender and type of treatment. 
Controlled Cox regression for gender, diagnose and treatment  
Variables Haz, Ratio Std, Err, P>|z|  CI95% 
Gender-female 1.14 0.496 0.075 0.489 1.678 
Gender-male 1 reference     
TTh+Metoprolol 0.89 0.383 0.072 0.344 1.053 
TTh+Carvedilol 0.82 0.313 0.041 0.283 1.680 
TTh+Nebivolol 0.96 0.643 0.047 0.270 0.999 
TTh 1 reference     
 
As it is shown above females have 14% higher probability of death 
compared to males. However, this is not highly significant 
(p=0.075). All combined treatments are advantageous compared 
to the traditional treatment. Patients who take Carvedilol 
alongside the traditional treatment have the highest advantage 
(18% lower hazard of death compared to the traditional 
treatment). Patients who take metoprolol alongside the traditional 
treatment have 11% lower hazard of death compared to those 
who are treated with the traditional medication. However, this is 
not highly significant p=0.072. Finally,patients who take Nebivolol 
have only a slight advantage compared to those who are treated 
with the traditional medication with only 4% lower hazard of 
death. This is status ally significant p=0.047. We cannot however, 
compare various treatments among themselves; we can only 
compare different treatments with the reference group-the 
traditional treatment. 
Another indicator with economic importance, that at the same time 
express the effectiveness of the treatment was the Average days of 
hospital stand, reflected below. 
 
Table 4: The average length of hospital stay (days) 
S. No. Type of treatment Average length of hospital stay (days)  
1. Treatment with metoprolol 12.25 
2. Treatment with carvedilol 10.48 
Average days of hospital stay for Metoprolol group were 12.25days/year, Average days of hospital stay for Carvedilol group were 10.48days/year.  
 
Estimation of costs 
The effectiveness of beta-blockers in patients with heart failure 
was demonstrated in some studies. However, the cost 
effectiveness of them remains to be established. To have a larger 
view of the necessary economic values for the treatment of CHF, 
the annual costs of treatment needs to be calculated. It was 
calculated the daily cost of drugs for every patient, daily cost of 
medical analysis and tests for every patient, and the value of 
hospital secondary expenses. 
The Average hospital daily cost for the patient in lek is higher of 
423lek(3.02 €) compared with the Average hospital daily cost with 
Metoprolol Group and 458 lek(3.27 €) more than Control Group. 
The total of the hospital costs for every patient with respective 
out of hospital costs per patient, gives us the annual cost of 
every patient. We have studied the average annual cost for the 
two types of treatment schemes (Traditional 
treatment+Carvedilol; Traditional treatment+ Metoprolol) and 
we have found the difference between them. 
 
Table 5: The average hospital daily cost for patients for carvedilol, metoprolol and control group(TTh) 
Groups according medication Hospital cost for patient/day 
Carvedilol Group 2736lek±52 (19.54 €) 
Metoprolol Group 2313lek±64 (16.52 €) 
Control Group(TTh) 2278 lek±88(16.27 €) 
 
Exchange rate 1euro=140lek 
 
Table 6: The average of annual cost for carvedilol, metoprolol groups 
S. No. The Average of annual Cost Value Difference between groups  
1 Metoprolol Group 54713 lek (390.8€) 30277 lek (216.26 €) 
2 Carvedilol Group 84990 lek (607.07€) 




The COMET study showed that carvedilol reduced mortality 
compared to metoprolol tartrate in patients with mild-moderate 
heart failure and left ventricular systolic dysfunction [4]. 
Our study confirms this conclusion. Patients treated with carvedilol 
18% less chance of death compared to the control group (p=0.041). 
Patients who take metoprolol have11% less chance of death 
compared to the control group (p=0.072, without statistical 
difference). In the two multi center studies [20, 21] treatments with 
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metoprolol for 12 to 18 months or with bisoprolol for 4 to 44 
months, was associated with fewer hospitalizations.  
Our study indicates that, carvedilol therapy was associated with a 
reduction in hospitalization for cardiovascular causes compared 
with metoprolol therapy. The decrease in hospitalizations for 
cardiovascular causes seen with carvedilol in our study reaffirms 
these earlier observations. 
We consider as a limitation of our study the small number of 
patients evaluated. It can seem that the study is limited only in one 
city, but the patients enrolled are representative of the whole 
country and not just of the Tirana city because this is the greatest 
cardiology center in Albania. 
CONCLUSION 
The findings of this study suggest the superiority of carvedilol 
compared to metoprolol 
in terms of efficacy and cost-effectiveness. The use of carvedilol 
along with the traditional therapy of heart failure patients assures a 
higher survival rate and a lower hospitalization rate (-1.77days of 
hospitalization for patient), but an increase of 216 € more a year 
when compared to the medication of metoprolol in addition with the 
traditional therapy. 
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